Automated insulin delivery after beta-cell replacement failure in people living with type 1 diabetes
Authors' conclusion
This study highlights the effectiveness of AID in achieving glucose control targets and preventing severe hypoglycemia in patients with T1D following βCR failure. AID may serve as a valuable therapeutic option to improve glucose control when graft function declines.
Study context
- Population
- People with T1D with βCR (islet or pancreas transplantation) failure, defined as secondary graft failure or marginal function, treated with automated insulin delivery (AID)
- Participants
- 23 people
- Exposure
- AID after βCR failure: before vs after 12 months
- AIDn = 23
- Outcome
- Proportion of patients achieving recommended glucose targets (TIR >70%, TBR <4% and HbA1c <7%)
Methodological detailsnational, multicentre
- National
- Multicentre
Main finding
As reported in the abstract
Proportion achieving recommended glucose targets · 12 months
Proportion achieving targets under AID, before → after 12 months
5.0 % to 57.1 %
Observational data: associations, not effects.
Secondary outcomes
TIR · 12 months
- TIR increased (mean ± SD)
- 54.2 ± 18.0 % to 75.5 ± 9.6 %
Glycemia risk index (GRI) · 12 months
- GRI decreased
- 45.8 ± 22.2 % to 25.6 ± 10.3 %
HbA1c · 12 months
- HbA1c decreased
- 7.5 ± 0.9 % to 7.0 ± 1.1 %
Coefficient of variation (CV), body weight and insulin doses
- CV, body weight and insulin doses did not change
AID discontinuation
- Patients discontinuing AID
- 0
Safety
- All patients free from severe hypoglycaemia under AID, including those with severe hypoglycaemia after βCR failure
Original publication
Automated insulin delivery after beta-cell replacement failure in people living with type 1 diabetes. Diabetes Metab. Published 21 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →